iX Biopharma focuses on the development and commercialisation of novel wafer formulations to improve the quality of life of those suffering from pain and other health conditions
Sat, Sep 19, 2020 - 5:50 AM
"China is a high-priority market and big growth driver for us. Australian-made health supplements are regarded by Chinese consumers as the gold standard of products due to the country's reputation for safety and quality. We expect this market to grow from strength to strength." - Janakan Krishnarajah, COO, iX Biopharma.
PHOTO: IX BIOPHARMA
SINCE joining Singapore Exchange (SGX)-listed specialty pharmaceutical company iX Biopharma, Janakan Krishnarajah has been getting involved in many new aspects of the drug making business.
Dr Krishnarajah, a specialist in the fields of clinical pharmacology and internal medicine, had...